Matthew Koc

Dr. Matthew Koc

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2018 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
DNDavid P. Nenon
David P. Nenon
KPKimo Pressler
Kimo Pressler
JKJun Kang
Jun Kang
BKBrent A. Koscher
Brent A. Koscher
JOJacob H. Olshansky
Jacob H. Olshansky
AAA. Paul Alivisatos
A. Paul Alivisatos

19 December 2016 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SRShilpa N. Raja
Shilpa N. Raja
YBYehonadav Bekenstein
Yehonadav Bekenstein
MKMatthew Koc
Matthew Koc
SFStefan Fischer
Stefan Fischer
DZDandan Zhang
Dandan Zhang
AAA. Paul Alivisatos
A. Paul Alivisatos

26 June 2017 in Nano Letters
Verified
Journal Article
Closed access
MJMatthew J. Jurow
Matthew J. Jurow
TLThomas Lampe
Thomas Lampe
EPErika Penzo
Erika Penzo
JKJun Kang
Jun Kang
MKMatthew Koc
Matthew Koc
YLYi Liu
Yi Liu

26 January 2017 in ACS Nano
Verified
Journal Article
Closed access
MKMatthew Koc
Matthew Koc
SRShilpa N. Raja
Shilpa N. Raja
LHLindsey A. Hanson
Lindsey A. Hanson
SNSon C. Nguyen
Son C. Nguyen
NBNicholas J. Borys
Nicholas J. Borys
AAA. Paul Alivisatos
A. Paul Alivisatos

1 November 2023 in Journal of Mass Spectrometry and Advances in the Clinical Lab
Verified
Journal Article
Open access
MKMatthew Koc
Matthew Koc
TWTimothy Aaron Wiles
Timothy Aaron Wiles
DWDaniel C. Weinhold
Daniel C. Weinhold
SRSteven Rightmyer
Steven Rightmyer
AWAmanda Laura Weaver
Amanda Laura Weaver
RIRobert W. Georgantas Iii
Robert W. Georgantas Iii
The VeriStrat® test (VS) is a blood-based assay that predicts a patient's response to therapy by analyzing eight features in a spectrum obtained from matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis of human serum and plasma. In a recent analysis of the INSIGHT clinical trial (NCT03289780), it was found that the VS labels, VS Good and VS Poor, can effectively predict the responsiveness of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitor (ICI) therapy. However, while VS measures the intensities of spectral features using MALDI-TOF analysis, the specific proteoforms underlying these features have not been comprehensively identified. The objective of this study was to identify the proteoforms that are measured by VS. To resolve the features obtained from the low-resolution MALDI-TOF procedure used to acquire mass spectra for VS DeepMALDI® analysis of serum was employed. This technique allowed for the identification of finer peaks within these features. Additionally, a combination of reversed-phase fractionation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was then used to identify the proteoforms associated with these peaks. The analysis revealed that the primary constituents of the spectrum measured by VS are serum amyloid A1, serum amyloid A2, serum amyloid A4, C-reactive protein, and beta-2 microglobulin. Proteoforms involved in host immunity were identified as significant components of these features. This newly acquired information improves our understanding of how VS can accurately predict patient response to therapy. It opens up additional studies that can expand our understanding even further.

17 July 2025 in The Astrophysical Journal Supplement Series
Verified
Journal Article
Open access
TBTanay Bhandarkar
Tanay Bhandarkar
SHSaianeesh K. Haridas
Saianeesh K. Haridas
JIJeff Iuliano
Jeff Iuliano
AKAnna Kofman
Anna Kofman
AMAlex Manduca
Alex Manduca
KZKaiwen Zheng
Kaiwen Zheng
The Simons Observatory (SO) is a ground-based cosmic microwave background (CMB) survey experiment that currently consists of three 0.42 m small-aperture telescopes and one 6 m large-aperture telescope (LAT), located at an elevation of 5200 m in the Atacama Desert in Chile. At the LAT’s focal plane, SO will install >62,000 transition-edge sensor detectors across 13 optics tubes (OTs) within the Large Aperture Telescope Receiver (LATR), the largest cryogenic camera ever built to observe the CMB. Here we report on the validation of the LATR in the laboratory and the subsequent dark testing and validation within the LAT. We show that the LATR meets cryogenic, optical, and detector specifications required for high-sensitivity measurements of the CMB. At the time of writing, the LATR is installed in the LAT with six OTs (corresponding to >31,000 detectors), and the LAT mirrors and remaining seven OTs are undergoing development.